LENZ - LENZ Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LENZ is currently covered by 2 analysts with an average price target of $44.72. This is a potential upside of $14.95 (50.22%) from yesterday's end of day stock price of $29.77.

LENZ Therapeutics's activity chart (see below) currently has 0 price targets and 5 ratings on display. The stock rating distribution of LENZ is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 76 days.

Highest price target for LENZ is $48, Lowest price target is $36, average price target is $42.

Most recent stock forecast was given by MATTHEW CAUFIELD from HC WAINWRIGHT on 28-Jul-2025. First documented stock forecast 27-Mar-2024.

Best performing analysts who are covering LENZ - LENZ Therapeutics:

Joseph Catanzaro Matthew Caufield

Currently out of the existing stock ratings of LENZ, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$48

$18.23 (61.24%)

$38

5 days ago
(28-Jul-2025)

0/3 (0%)

$16.49 (52.33%)

Buy

$36

$6.23 (20.93%)

$28

11 months 18 days ago
(15-Aug-2024)

2/2 (100%)

$13.4 (59.29%)

152

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LENZ (LENZ Therapeutics) average time for price targets to be met?

On average it took 76 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on LENZ (LENZ Therapeutics) with a proven track record?

JOSEPH CATANZARO

Which analyst has the current lower performing score on LENZ (LENZ Therapeutics) with a proven track record?

MATTHEW CAUFIELD

Which analyst has the most public recommendations on LENZ (LENZ Therapeutics)?

Joseph Catanzaro works at PIPER SANDLER and has 9 price targets and 7 ratings on LENZ

Which analyst is the currently most bullish on LENZ (LENZ Therapeutics)?

Matthew Caufield with highest potential upside - $18.23

Which analyst is the currently most reserved on LENZ (LENZ Therapeutics)?

Joseph Catanzaro with lowest potential downside - $6.23

LENZ Therapeutics in the News

LENZ Therapeutics gets FDA nod for presbyopia eye drop

[Female scientist examining toxic liquid in laboratory.] skynesher/E+ via Getty Images * LENZ Therapeutics (NASDAQ:LENZ [https://seekingalpha.com/symbol/LENZ]) said that the U.S. FDA approved its eye drop, Vizz (aceclidine ophthalmic solution) 1.44%, for the treatment of presbyopia in adults. * The company stated [https://seekingalpha.com/pr/20185596-lenz-therapeutics-announces-us-fda-approval-of-vizz-for-the-treatment-of-presbyopia]that it expects the commercial product to be widely accessible by mid-Q4 2025, with...

Lenz Therapeutics stock gains as William Blair reiterates Outperform

Investing.com – Lenz Therapeutics Inc (NASDAQ:LENZ) stock gained after William Blair reiterated its Outperform rating on the presbyopia treatment developer. The stock has shown strong momentum, rising nearly 11% in the past week, with analysts maintaining a Strong Buy consensus and price targets ranging from $36 to $60. InvestingPro analysis reveals 10+ additional expert insights...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?